Feedback / Questions
CLD-423 - Caldera Therapeutics
https://www.businesswire.com/news/home/20260114598329/en/Caldera-Therapeutics-Launches-with-%24112.5-Million-and-Announces-First-Subjects-Dosed-in-Phase-1-Trial-of-First-In-Class-Bispecific-Antibody-CLD-423-for-Inflammatory-Bowel-Disease
Jan 14, 2026
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next